Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
1998 13
1999 2
2000 5
2001 9
2002 18
2003 22
2004 35
2005 30
2006 40
2007 29
2008 31
2009 26
2010 27
2011 31
2012 23
2013 24
2014 21
2015 32
2016 23
2017 17
2018 22
2019 20
2020 12
2021 22
2022 21
2023 19
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

536 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Donepezil for dementia due to Alzheimer's disease.
Birks JS, Harvey RJ. Birks JS, et al. Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3. Cochrane Database Syst Rev. 2018. PMID: 29923184 Free PMC article. Review.
OBJECTIVES: To assess the clinical efficacy and safety of donepezil in people with mild, moderate or severe dementia due to Alzheimer's disease; to compare the efficacy and safety of different doses of donepezil; and to assess the effect of donepezil on healt …
OBJECTIVES: To assess the clinical efficacy and safety of donepezil in people with mild, moderate or severe dementia due to Alzheimer …
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Howard R, et al. N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668. N Engl J Med. 2012. PMID: 22397651 Free article. Clinical Trial.
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 3 …
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate o …
Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis.
Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Guo J, et al. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. Brain Behav. 2020. PMID: 32914577 Free PMC article.
INTRODUCTION: Alzheimer's disease (AD) is a degenerative brain disease that progresses over time, heavily burdening patients, families, and aging societies worldwide. Memantine and donepezil are frequently used in its treatment, both as monotherapy and in combination. ...M …
INTRODUCTION: Alzheimer's disease (AD) is a degenerative brain disease that progresses over time, heavily burdening patients, families, and …
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Hansen RA, et al. Clin Interv Aging. 2008;3(2):211-25. Clin Interv Aging. 2008. PMID: 18686744 Free PMC article. Review.
Three open-label trials and one double-blind randomized trial directly compared donepezil with galantamine and rivastigmine. Results are conflicting; two studies suggest no differences in efficacy between compared drugs, while one study found donepezil to be more ef …
Three open-label trials and one double-blind randomized trial directly compared donepezil with galantamine and rivastigmine. Results …
Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study.
Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Bago Rožanković P, et al. Cogn Behav Neurol. 2021 Dec 2;34(4):288-294. doi: 10.1097/WNN.0000000000000285. Cogn Behav Neurol. 2021. PMID: 34851866 Clinical Trial.
OBJECTIVE: To evaluate the effects of donepezil and memantine in relieving BPSD in individuals with moderate AD. METHOD: We conducted a prospective, randomized, 6-month clinical trial involving 85 individuals with moderate AD divided into two groups: group 1 (n = 42) was t …
OBJECTIVE: To evaluate the effects of donepezil and memantine in relieving BPSD in individuals with moderate AD. METHOD: We conducted …
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Tan CC, et al. J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690. J Alzheimers Dis. 2014. PMID: 24662102 Review.
No behavioral benefits were observed, except for -2.72 (95% CI -4.92 to -0.52) in the 10 mg daily donepezil group and -1.72 (95% CI -3.12 to -0.33) for 24 mg daily galantamine trial. Only 5 mg daily donepezil had no effect on the function outcome. Compared with plac …
No behavioral benefits were observed, except for -2.72 (95% CI -4.92 to -0.52) in the 10 mg daily donepezil group and -1.72 (95% CI - …
Differential response to donepezil in MRI subtypes of mild cognitive impairment.
Diaz-Galvan P, Lorenzon G, Mohanty R, Mårtensson G, Cavedo E, Lista S, Vergallo A, Kantarci K, Hampel H, Dubois B, Grothe MJ, Ferreira D, Westman E. Diaz-Galvan P, et al. Alzheimers Res Ther. 2023 Jun 23;15(1):117. doi: 10.1186/s13195-023-01253-2. Alzheimers Res Ther. 2023. PMID: 37353809 Free PMC article. Clinical Trial.
BACKGROUND: Donepezil is an approved therapy for the treatment of Alzheimer's disease (AD). ...METHODS: From the Hippocampus Study double-blind, randomized clinical trial, we included 173 MCI individuals (donepezil = 83; placebo = 90) with structural MRI data, at ba …
BACKGROUND: Donepezil is an approved therapy for the treatment of Alzheimer's disease (AD). ...METHODS: From the Hippocampus Study do …
Efficacy and safety of donepezil for mild cognitive impairment: A systematic review and meta-analysis.
Zhang X, Lian S, Zhang Y, Zhao Q. Zhang X, et al. Clin Neurol Neurosurg. 2022 Feb;213:107134. doi: 10.1016/j.clineuro.2022.107134. Epub 2022 Jan 19. Clin Neurol Neurosurg. 2022. PMID: 35078087 Review.
OBJECTIVE: This study intends to systematically evaluate the efficacy and safety of donepezil for improving cognitive function in patients with mild cognitive impairment (MCI), and to provide evidence-based foundation for donepezil in MCI treatment. ...CONCLUSION: …
OBJECTIVE: This study intends to systematically evaluate the efficacy and safety of donepezil for improving cognitive function in pat …
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Tariot PN, et al. JAMA. 2004 Jan 21;291(3):317-24. doi: 10.1001/jama.291.3.317. JAMA. 2004. PMID: 14734594 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled clinical trial of 404 patients …
OBJECTIVE: To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatm …
Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial.
Osataphan N, Phrommintikul A, Leemasawat K, Somwangprasert A, Apaijai N, Suksai S, Sirikul W, Gunaparn S, Chattipakorn SC, Chattipakorn N. Osataphan N, et al. Sci Rep. 2023 Aug 7;13(1):12759. doi: 10.1038/s41598-023-40061-4. Sci Rep. 2023. PMID: 37550350 Free PMC article. Clinical Trial.
Metformin (n = 43), donepezil (n = 52), or placebo (n = 48) were prescribed during DOX treatment. ...Metformin and donepezil did not attenuate hsTnI elevation, LVEF or GLS reduction. ...
Metformin (n = 43), donepezil (n = 52), or placebo (n = 48) were prescribed during DOX treatment. ...Metformin and donepezil d …
536 results